STEMLINE THERAPEUTICS INC

NEW YORK, NY How do I update this listing?

Create Email Alert

Stemline Therapeutics is based out of New York. Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas.Whalewisdom has at least 73 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2012-01-17. The notice included securities offered of Debt,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security

Contact Info

stemline therapeutics inc
750 LEXINGTON AVENUE
NEW YORK NY    10022

Business Phone: 212-831-1111
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year

Loading...

Form D Filings

Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2012-01-17 D PHARMACEUTICALS Debt,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security INDEFINITE 740,000 INDEFINITE
2010-04-27 D PHARMACEUTICALS Equity 600,000 600,000 0
2010-03-29 D PHARMACEUTICALS Equity,Other 1,250,000 1,250,000 0
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
IVAN BERGSTEIN subscription required
    EXECUTIVE OFFICER DIRECTOR
RONALD BENTSUR subscription required
    DIRECTOR
IVAN BERGSTEIN, M.D. subscription required
    EXECUTIVE OFFICER DIRECTOR

Elevate your investments